


INTRODUCTION AND JUSTIFICATION

- Pulmonary Embolism (PE) affects more than 900,000 Americans annually with an estimated 60,000 – 100,000 deaths per year and an estimated one-month mortality rate of 10%-30%¹.
- According to the American Heart Association (AHA), risk stratification of PE's is categorized as either massive (MPE), submassive (SPE), or non-massive based on various hemodynamic and clinical factors.
- The Emergency Department (ED) is often utilized for management and subsequent prevention of further adverse outcomes of PE, but diagnostic and therapeutic challenges arise due to variability in presentation and response to treatment.
- The Pulmonary Embolism Severity Index (PESI) is a composite metric that can also be used to determine prognosis of PE in the ED as a 30day outcome, informing treatment options through a 5-point scale.
- AHA supports Catheter-Directed Thrombolysis (CDT) or Systemic Thrombolysis (ST) involving alteplase administration for management of an MPE, which has been shown to raise the risk of adverse outcomes post intervention with no standard of care recommended for SPE.
- These outcomes and uncertainties make it imperative to determine the benefits and adverse outcomes associated with either treatment for both MPE and SPE while also seeing if existing tools can be used as a clinical decision tool for ED physicians.
- The objective of this study is to analyze CDT or ST/no treatment for outcomes and investigate PESI profiles for each treatment among for MPE and SPE patients. This analysis can inform ED management and cardiovascular interventions for a spectrum of healthcare professionals.

METHODS

- In this retrospective study, data was obtained via 2 methods Inclusion criteria: Patient > 18 years of age presenting with an MPE or SPE and received treatment based on their group
- Both prisoners and pregnant patients were excluded from this study
- EMR data was reviewed twice by different teams across all metrics collected including demographics, vital signs, medical history, serum biomarkers (e.g. troponin and NT-proBNP) and echocardiography.
- PESI was spit into low risk (tiers 1,2) and high-risk (tiers 3,4,5,).



Comparators were defined and logistics regressions + Chi-Squared

¹ Beckman, M. G., W. C. Hooper, S. E. Critchley, and T. L. Ortel. "Venous Thromboembolism: A Public Health Concern." [In eng]. Am J Prev Med 38, no. 4 Suppl (Apr 2010): S495-501.

Catheter Directed Thrombolysis As a Modality of Management For Pulmonary Embolism: Risk Stratifying with Pulmonary Embolism **Severity Index**

Dhruvil Patel B.S., Brian Reed M.S., Vijaya Arun Kumar M.D., M.P.H. Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, Michigan

Table 1: Defining Outcomes and Ana Subpopulations with Adverse or Positiv	
Outcome	Catego Corre
Negative Outcomes	• Dem
Bleeding Complications	 Puln (PES)
Mortality	 Inpat
Right Ventricular Dilation	Biom
Positive Outcome	Natri • Histo
Decrease in RV Hypokinesis between baseline and post CDT echo (Attribute of RV Dysfunction)	AnticPresLeng

RESULTS

Table 2: Value of Variables Post Propensity Score Match Between the Cases and Control Groups									
Variable Nam	Ne Value A Both Gr N = 33	oups:	Cases: N = 168 (%)	Controls N = 168 (%)	p (2-tailed)				
Race									
African American	224 (6	6.7)	107 (63.7)	117 (69.6)	0.247				
White/Other	112 (3	33.3)	61 (36.3)	51 (30.4)					
Age			60.8	0.631					
BMI			33.94		0.540				
Gender									
Male	163 (4	8.5)	79 (47.0)	84 (50.0)	0.585				
Female	173 (5	51.5)	89 (53.0)	84 (50.0)					
PESI									
Low Risk (1-2	2) 96 (2	8.6)	46 (27.4)	50 (29.4)	0.629				
High Risk (3-5	5) 240 (7	'1.4)	122 (72.6)	118 (70.2)					
PE Status									
Massive	208 (6	61.9)	102 (60.7)	106 (63.1)	0.653				
Submassive	128 (3	88.1)	66 (39.3)	62 (36.9)					
Table	3: Analysis	of Com	parators Agains	t Each Treatment	Modality				
		s: N = 168 (%) Controls: N = 1 (%)							
Bleeding Complications									
Present	40 (11.9)		13 (18.5)	9 (5.4)	0.0003				
Not Present	296 (88.1)	1	37 (81.6)	159 (94.6)					
			Mortality						
Yes	20 (6.0)		9 (5.4)	11 (6.5)	0.645				
No	316 (94.0)	1	159 (94.6)	157 (93.5)					
			nt Ventricular Di						
Yes	130 (38.7)			10 (7.7) at admiss	ion <i>0.0131</i>				
No	220 (64 2)		o 46 (35.4)	to 28 (21.5)					
No	230 (61.3)	pos	t-procedure	post-procedur					
Decrease in RV Hypokinesis Between Baseline and Post- CDT									
Yes	93 (27.7)			5 (5.4) at admissi	on <i>0.0133</i>				
			o 34 (36.6)	to 11 (11.8)					
	242 (72.2)	pos	t-procedure	post-procedure					
No	243 (72.3)								

Second data set was collected

analysis were done between metrics and comparators using SPSS.

Against Variables To Determine mes With Each Treatment Modality

ory of Variables Hypothesized to be related with All Outcome Between **Both Treatments**

nographic Hospital Index monary Embolism Severity Index

atient Procedures and Medication markers (e.g. Troponin and Brain riuretic Peptide) tory of PE or DVT icoagulant use sence of Hypertension ngth of Stay

• History of Aspirin use

						, V
		RESI	JLTS CO	NT.		
	Table 4: Inv	estigatio	on of PESI Aga	inst Co	omparators	5
Comparators	PESI Cat	egory	Cases (%)	Control (%)		P (2-tailed)
Mortality	Low Risk (N=96)		2 (2.1)	0 (0.0)		0.170
	High Risk		9 (3.8)	9 (3.8)		0.941
Bleeding	Low Risk (N=96)		10 (10.4)	0 (0.0)		0.001
Complications	High Risk (N=240)		21 (8.8)	9 (3.8)		0.015
Length of Stay	Low Risk	(N=96)	5.5 (5.7)	3.8 (4.0)		0.013
(Days)	High Risk (N=240)		9.4 (3.9)	6.9 (2.9)		0.005
	-	Associat	ession Analysi ed with Positiv tients (N = 186	ve or A	-	barators and Itcomes in CD1
Both		Both N	esized Correlate (In /IPE and SPE) from its who underwent CDT		(2-tailed)	
Mortali	Mortality		ed Brain Natriu Pentide (BNP)	retic		0.015
		Peptide (BNF History of Deep Thrombosis (D				0.043
Bleeding Com			ory of Aspirin L of Hospitaliza			0.012 0.015
Baseline and	crease in RV tinesis Between ne and Post-CDT EchoNo correlates were significant or close to being significant					
		CON	ICLUSIO	NS		
 more effection bleeding constant Regardless associated value length of ho Further study 	ve than the mplications of PESI so with a grea spital stay dies need t	e other s among core, it d ater incid	dence in com	ow a sunder on that oplicat	significant went CDT CDT inte tions as w	increase in F. rvention was cell as a longe
		LIN		S		
• While the int viable, it can	•	• •	ensity matchi by controlling	Ŭ		
	FU	TUR	E DIRECT	ION	S	
 produce a n further char among SPE Use this and physicians t 	iuanced ar acteristics and MPE alysis to de	alysis of that car patient evelop a	s. a novel decisi	zed ou dverse ion-m	utcomes t e or positi aking algo	o determine ive outcomes

also saving crucial time.

000